[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361519-105":59,"doc-detail-361519-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","parp-inhibitors-across-different-malignancies-clinical-applications-resistance-mechanisms-and-strategies-to-enhance-efficacy-through-combination-therapies","PARP inhibitors across different malignancies - clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies","","Poly-ADP-ribose polymerase (PARP) inhibitors are presented as targeted anticancer agents that exploit synthetic lethality by disrupting defective DNA repair, especially homologous recombination (HR) pathways. The review consolidates evidence for clinical use beyond established BRCA1/2 indications, covering multiple malignancies and summarizing emerging data on solid tumors with HR defects. It highlights combination-therapy strategies, resistance mechanisms, and future perspectives intended to broaden therapeutic efficacy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parp-inhibitors-across-different-malignancies-clinical-applications-resistance-mechanisms-and-strategies-to-enhance-efficacy-through-combination-therapies/361519/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parp-inhibitors-across-different-malignancies-clinical-applications-resistance-mechanisms-and-strategies-to-enhance-efficacy-through-combination-therapies/361519.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What principle do PARP inhibitors use to kill tumor cells?","Question",{"text":113,"@type":114},"PARP inhibitors exploit synthetic lethality by disrupting defective DNA repair pathways, particularly when homologous recombination (HR) is impaired.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which cancers have PARP inhibitors shown strong clinical relevance for?",{"text":118,"@type":114},"They are established in first- and later-line therapies for breast, prostate, pancreatic, and ovarian cancers, especially those with BRCA1/2 mutations.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is resistance an important issue for PARP inhibitor therapy?",{"text":122,"@type":114},"The review emphasizes resistance mechanisms and discusses combination strategies designed to enhance efficacy and address therapeutic limitations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},361519,1790154158,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","TYPE Review  \nPUBLISHED 01 September 2026 DOI 10.3389/fcell.2026.1891797  \n PARP inhibitors across different  \nOPEN ACCESS  \nEDITED BY  \nLaura Ancuta Pop,  \nUniversity of Medicine and Pharmacy Iuliu Hatieganu, Romania  \nREVIEWED BY  \nFabrizio Di Costanzo,  \nNewcastle University, United Kingdom Wajid Ahmad,  \nSant Gadge Baba Amravati University, India  \n*CORRESPONDENCE  \nHicham Mansour,  \n [h.mansour@ump.ac.ma](h.mansour@ump.ac.ma)  \n†These authors have contributed equally to this work and share first authorship  \nRECEIVED 26 May 2026  \nREVISED 03 August 2026  \nACCEPTED 03 August 2026  \nPUBLISHED 01 September 2026  \nCITATION  \nOuhajjou A, Mazouji O, Nejjari C, Incitti Rand Mansour H (2026) PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies.  \nFront. Cell Dev. Biol. 14:1891797 .  \ndoi: 10.3389/fcell.2026.1891797  \nCOPYRIGHT  \n© 2026 Ouhajjou, Mazouji, Nejjari, Incitti and Mansour. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nmalignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies  \nAbdelhak Ouhajjou 1†, Omayma Mazouji 2†, Chakib Nejjari 3,4, Roberto Incitti 3 and Hicham Mansour 2,3*  \n1Al-Azhar Oncology Center, Rabat, Morocco, 2GES-LCM2E, FSA, Mohamed First University, Nador, Morocco, 3Euromed Research Center, Euromed University of Fes, Fes, Morocco, 4Faculty of Medicine, Pharmacy, and Dentistry, Sidi Mohamed Ben Abdellah University, Fes, Morocco  \nPoly-ADP-ribose polymerase (PARP) inhibitors represent a novel class of anticancer agents that leverage the principle of synthetic lethality to induce tumor cell death by disrupting defective DNA repair pathways. PARP inhibitors have demonstrated strong preclinical activity in tumors with homologous recombination (HR) repair deficiencies. The discovery of synthetic lethality between HR defects and PARP inhibition led to multiple clinical trials, first in BRCA1/2-mutated cancers and later in other HR-deficient tumors. PARP inhibitors have become essential components of first-and later-line therapies for breast, prostate, pancreatic, and ovarian cancers, with several agents already approved by the FDA. However, their therapeutic potential in other malignancies remains less defined, as limited studies have explored their efficacy in additional solid tumors. This article provides an updated overview of PARP inhibitors use beyond their established clinical indications, highlighting current evidence, combination strategies, and emerging perspectives that may expand their role in various cancer treatment including endometrial cancer, cervical cancer, kidney cancer, colorectal cancer, non–small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and other malignancies.  \nKEYWORDS  \ncancer, PARP inhibitors, precision oncology, resistance, treatment  \nIntroduction  \nPoly ADP-ribose polymerase inhibitors (PARPi) have revolutionized cancer therapy, particularly in tumors with defects in homologous recombination repair (HRR) genes such as BRCA1 and BRCA2 (Lin et al., 2024). They represent one of the earliest and most prominent examples of the synthetic lethality approach in oncology describing a genetic interaction in which the loss of function of either gene alone does not impair cell viability, whereas their simultaneous inactivation leads to cell death. This loss of function may result from inactivating mutations, gene deletion, or pharmacological inhibition. PARP inhibition has been shown to initiate synthetic lethali","cbCaifpiBglarV3k","https://ap.wps.com/l/cbCaifpiBglarV3k","pdf",3194283,27,"English","# Introduction\n# Methodology","[{\"question\":\"What principle do PARP inhibitors use to kill tumor cells?\",\"answer\":\"PARP inhibitors exploit synthetic lethality by disrupting defective DNA repair pathways, particularly when homologous recombination (HR) is impaired.\"},{\"question\":\"Which cancers have PARP inhibitors shown strong clinical relevance for?\",\"answer\":\"They are established in first- and later-line therapies for breast, prostate, pancreatic, and ovarian cancers, especially those with BRCA1/2 mutations.\"},{\"question\":\"Why is resistance an important issue for PARP inhibitor therapy?\",\"answer\":\"The review emphasizes resistance mechanisms and discusses combination strategies designed to enhance efficacy and address therapeutic limitations.\"}]","PARP inhibitors across different malignancies - clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies | PDF",1790144664,68,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55664b09cab32a3cf018b1a0cc454645.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/938ea6354aff2de5802da756d1a0fcbd.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7936ce2b57da824d5ff46a23dd0e5233.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8faa760aa84b95f7ea92d60045841c6a.webp",980,1385]